Aclaris Therapeutics, Inc.

ACRS

Healthcare|Biotechnology|US

$3.90

+0.29 (+8.03%)

Tangible Book / Share

$1.12

Cash / Share

$0.76

Next Earnings Report

Feb 25, 2027

EPS est. -$0.16 · Revenue est. $1.4M

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Oct 27, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Jun 2027

Est. completion

P1Metastatic Pancreatic Ductal Adenocarcinoma

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT06648434n=51

May 2032

Est. completion

P1P2Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459n=152

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706

Recent Press Releases

Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Nov 5, 2026 · GlobeNewsWire

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

Oct 27, 2026 · GlobeNewsWire

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Oct 27, 2026 · GlobeNewsWire

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Sep 3, 2026 · GlobeNewsWire

SEC Filings (72)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	10-Q	Quarterly report	Document Index
Nov 5, 2026	8-K	Material event	Document Index
Oct 27, 2026	8-K	Material event	Document Index
Oct 27, 2026	424B5	Offering prospectus	Document Index
Oct 27, 2026	8-K	Material event	Document Index
Sep 21, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 6, 2026	8-K	Material event	Document Index
Aug 6, 2026	S-3ASR	Shelf registration	Document Index
Aug 6, 2026	10-Q	Quarterly report	Document Index
Aug 6, 2026	8-K	Material event	Document Index
Jun 4, 2026	8-K	Material event	Document Index
May 12, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 7, 2026	10-Q	Quarterly report	Document Index
May 7, 2026	8-K	Material event	Document Index
Apr 28, 2026	8-K	Material event	Document Index
Apr 27, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Apr 23, 2026	ARS	Annual report to holders	Document Index
Apr 23, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 23, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 7, 2026	SC 13G	Passive 5%+ stake	Document Index
Mar 26, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Mar 17, 2026	SC 13G	Passive 5%+ stake	Document Index
Mar 11, 2026	8-K	Material event	Document Index
Mar 10, 2026	8-K	Material event	Document Index
Feb 26, 2026	10-K	Annual report	Document Index
Feb 26, 2026	8-K	Material event	Document Index
Feb 9, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jan 21, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jan 12, 2026	8-K	Material event	Document Index
Jan 9, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jan 6, 2026	8-K	Material event	Document Index
Nov 13, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Nov 6, 2025	10-Q	Quarterly report	Document Index
Nov 6, 2025	8-K	Material event	Document Index
Oct 14, 2025	8-K	Material event	Document Index
Aug 7, 2025	10-Q	Quarterly report	Document Index
Aug 7, 2025	8-K	Material event	Document Index
Jul 29, 2025	8-K	Material event	Document Index
Jul 29, 2025	SC 13G	Passive 5%+ stake	Document Index